LoRusso PM - Search Results

1

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Infante JR, Hollebecque A, Postel-Vinay S, Bauer TM, Blackwood EM, Evangelista M, Mahrus S, Peale FV, Lu X, Sahasranaman S, Zhu R, Chen Y, Ding X, Murray ER, Schutzman JL, Lauchle JO, Soria JC, LoRusso PM. Infante JR, et al. Among authors: lorusso pm. Clin Cancer Res. 2017 May 15;23(10):2423-2432. doi: 10.1158/1078-0432.CCR-16-1782. Epub 2016 Nov 4. Clin Cancer Res. 2017. PMID: 27815358 Clinical Trial.

2

Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.

LoRusso P, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH. LoRusso P, et al. Cancer Res. 1990 Aug 15;50(16):4900-5. Cancer Res. 1990. PMID: 2165850

3

Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems.

LoRusso PM, Aukerman SL, Polin L, Redman BG, Valdivieso M, Biernat L, Corbett TH. LoRusso PM, et al. Cancer Res. 1990 Sep 15;50(18):5876-82. Cancer Res. 1990. PMID: 2393858

4

Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma.

LoRusso P, Pazdur R, Redman BG, Kinzie J, Vaitkevicius V. LoRusso P, et al. Am J Clin Oncol. 1989 Dec;12(6):486-90. doi: 10.1097/00000421-198912000-00005. Am J Clin Oncol. 1989. PMID: 2686394 Review.

5

Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.

Ramnath N, LoRusso P, Simon M, Martino S. Ramnath N, et al. Am J Clin Oncol. 1997 Aug;20(4):368-72. doi: 10.1097/00000421-199708000-00009. Am J Clin Oncol. 1997. PMID: 9256891 Clinical Trial.

6

Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.

Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH. Foster BJ, et al. Among authors: lorusso pm. Clin Cancer Res. 1997 Nov;3(11):2047-53. Clin Cancer Res. 1997. PMID: 9815596

7

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).

LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L. LoRusso P, et al. Clin Cancer Res. 1995 Dec;1(12):1487-93. Clin Cancer Res. 1995. PMID: 9815948 Clinical Trial.

8

Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.

Foster BJ, Wiegand RA, LoRusso PM, Baker LH. Foster BJ, et al. Among authors: lorusso pm. Clin Cancer Res. 1995 Aug;1(8):831-7. Clin Cancer Res. 1995. PMID: 9816052

9

Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.

Keyes KA, Albella B, LoRusso PM, Bueren JA, Parchment RE. Keyes KA, et al. Among authors: lorusso pm. Clin Cancer Res. 2000 Jun;6(6):2474-81. Clin Cancer Res. 2000. PMID: 10873102

10

Phase I pharmacokinetic study of the novel antitumor agent SR233377.

LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH. LoRusso PM, et al. Clin Cancer Res. 2000 Aug;6(8):3088-94. Clin Cancer Res. 2000. PMID: 10955788 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

344 results

Search Page

Filters